Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage clinical pipeline support.

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as ...

For BIIB, these are the biggest forces that could help or hurt the stock's price. 1. Tecfidera: Above all else, if Biogen is to thrive and if BIIB stock is to advance, its MS drug needs to do well.